PL3331892T3 - Sposób wytwarzania pochodnych kwasu GalNAc - Google Patents

Sposób wytwarzania pochodnych kwasu GalNAc

Info

Publication number
PL3331892T3
PL3331892T3 PL16745745T PL16745745T PL3331892T3 PL 3331892 T3 PL3331892 T3 PL 3331892T3 PL 16745745 T PL16745745 T PL 16745745T PL 16745745 T PL16745745 T PL 16745745T PL 3331892 T3 PL3331892 T3 PL 3331892T3
Authority
PL
Poland
Prior art keywords
processes
preparation
acid derivatives
galnac acid
galnac
Prior art date
Application number
PL16745745T
Other languages
English (en)
Polish (pl)
Inventor
Joerg Lill
RENé TRUSSARDI
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL3331892T3 publication Critical patent/PL3331892T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08Polyoxyalkylene derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/20Diazonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/10Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C07C67/11Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16745745T 2015-08-06 2016-08-02 Sposób wytwarzania pochodnych kwasu GalNAc PL3331892T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180058 2015-08-06
PCT/EP2016/068361 WO2017021385A1 (en) 2015-08-06 2016-08-02 Processes for the preparation of galnac acid derivatives
EP16745745.6A EP3331892B1 (en) 2015-08-06 2016-08-02 Processes for the preparation of galnac acid derivatives

Publications (1)

Publication Number Publication Date
PL3331892T3 true PL3331892T3 (pl) 2019-11-29

Family

ID=54056068

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16745745T PL3331892T3 (pl) 2015-08-06 2016-08-02 Sposób wytwarzania pochodnych kwasu GalNAc

Country Status (14)

Country Link
US (1) US10597417B2 (enExample)
EP (1) EP3331892B1 (enExample)
JP (1) JP6940477B2 (enExample)
KR (1) KR102579520B1 (enExample)
CN (1) CN107709342B (enExample)
AU (1) AU2016302697B2 (enExample)
CA (1) CA2982825C (enExample)
ES (1) ES2744437T3 (enExample)
HR (1) HRP20191589T1 (enExample)
IL (1) IL256528B (enExample)
MX (1) MX369556B (enExample)
PL (1) PL3331892T3 (enExample)
SI (1) SI3331892T1 (enExample)
WO (1) WO2017021385A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215049A1 (en) * 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
EP3743116B1 (en) * 2018-01-26 2024-07-10 F. Hoffmann-La Roche AG Radiolabelled oligonucleotides and process for their preparation
BR112020013431A2 (pt) * 2018-01-29 2020-12-01 F. Hoffmann-La Roche Ag processo para a preparação de conjugados de galnac-oligonucleotídeo
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
EP3972984A1 (en) * 2019-05-20 2022-03-30 F. Hoffmann-La Roche AG Process for the preparation of galnac phosphoramidite epimers
CA3140410A1 (en) 2019-06-20 2020-12-24 Martin Edelmann Radiolabeled moem type oligonucleotides and process for their preparation
CN110734372B (zh) * 2019-09-30 2024-09-24 兰州交通大学 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸(apea-9)的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US133170A (en) * 1872-11-19 Improvement in wheelbarrows
US156917A (en) * 1874-11-17 Improvement in car-couplings
US1185198A (en) * 1912-11-25 1916-05-30 Elliott Co Tube-cleaning apparatus.
JP5004234B2 (ja) * 2006-11-10 2012-08-22 独立行政法人産業技術総合研究所 膜マイクロドメイン又はコレステロール認識タンパク質検出用高感度分子プローブ
KR20110082601A (ko) * 2008-12-19 2011-07-19 피너클 파마수티칼스, 인코포레이티드 페나조피리딘 화합물
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2011053614A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Crystalline cdm-nag and methods for producing same
ES2562817T3 (es) * 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip
EA022078B1 (ru) * 2010-08-10 2015-10-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20130132475A (ko) * 2010-12-17 2013-12-04 애로우헤드 리서치 코오포레이션 siRNA의 갈락토오스 클러스터-약동학적 조절제 표적 물질
KR102482890B1 (ko) 2013-05-01 2022-12-30 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
JP2017501684A (ja) * 2013-11-14 2017-01-19 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S Apobアンチセンスコンジュゲート化合物
SI3137605T1 (sl) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega

Also Published As

Publication number Publication date
HRP20191589T1 (hr) 2019-12-13
BR112017021926A2 (pt) 2018-07-03
CN107709342B (zh) 2021-09-03
SI3331892T1 (sl) 2019-10-30
KR20180030783A (ko) 2018-03-26
EP3331892B1 (en) 2019-07-03
JP6940477B2 (ja) 2021-09-29
IL256528A (en) 2018-02-28
WO2017021385A1 (en) 2017-02-09
CA2982825C (en) 2023-10-17
HK1250717A1 (zh) 2019-01-11
KR102579520B1 (ko) 2023-09-15
JP2018523643A (ja) 2018-08-23
AU2016302697A1 (en) 2017-10-26
AU2016302697B2 (en) 2020-10-29
MX369556B (es) 2019-11-12
EP3331892A1 (en) 2018-06-13
IL256528B (en) 2020-01-30
MX2017015662A (es) 2018-04-18
CN107709342A (zh) 2018-02-16
US20180162894A1 (en) 2018-06-14
US10597417B2 (en) 2020-03-24
ES2744437T3 (es) 2020-02-25
CA2982825A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
HUE059158T2 (hu) Eljárás pridopidin elõállítására
IL258922A (en) Methods for the preparation of obeticholic acid and derivatives thereof
ZA201706795B (en) Process for the preparation of dicycloplatin
IL256528A (en) Processes for the preparation of the history of galnac acid
ZA201700254B (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
IL248267B (en) A process for preparing converted cycloserines
PT3298047T (pt) Processo para a preparação de polissacáridos
ZA201801991B (en) Process for the preparation of monochloroacetic acid
GB2561089B (en) Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one
SI3253772T1 (sl) Postopek za pripravo diosmina
IL247443B (en) Process for the preparation of 5-fluorotryptophol
GB2564185B (en) Process for the preparation of derivatives of benzodioxole
ZA201708170B (en) Process for the preparation of sodium cyanide
EP3148977A4 (en) Process for the preparation of 4-dimethylaminocrotonic acid
EP3227260A4 (en) Process for the preparation of levulinic acid
IL241974A0 (en) Process for making erlotinib
IL253562A0 (en) A method for the preparation of tyrazoles
HUP1500034A1 (en) Process for the preparation of vortioxetine salts
EP3344249A4 (en) Processes for the preparation of ivacaftor